CAS 1402709-93-6

CCT241736

CAS: 1402709-93-6

Fórmula: C₂₂H₂₃Cl₂N₇

Pureza: 95%

Cor e Forma: Solid

Peso molecular: 456.3709

Ref: IN-DA01ENWX

6-Chloro-7-(4-(4-Chlorobenzyl)Piperazin-1-Yl)-2-(1,3-Dimethyl-1H-Pyrazol-4-Yl)-1H-Imidazo[4,5-B]Pyridine

CAS: 1402709-93-6

6-Chloro-7-(4-(4-Chlorobenzyl)Piperazin-1-Yl)-2-(1,3-Dimethyl-1H-Pyrazol-4-Yl)-1H-Imidazo[4,5-B]Pyridine

Pureza: 98%

Peso molecular: 456.37g/mol

Ref: 54-OR1023173

CCT241736

CAS: 1402709-93-6

CCT241736

Pureza: ≥95%

Peso molecular: 456.37g/mol

Ref: 54-BUP10140

CCT241736

CAS: 1402709-93-6

CCT241736 is an orally bioavailable dual FLT3/Aurora kinase inhibitor that also inhibits clinically relevant FLT3-resistant mutants including FLT3-ITD and FLT3

Fórmula: C₂₂H₂₃Cl₂N₇

Pureza: 96.2% - 99.81%

Cor e Forma: Solid

Peso molecular: 456.37

Ref: TM-T4428

CCT241736

CAS: 1402709-93-6

CCT241736 is an effective dose of a clinical drug that belongs to the class of kinase inhibitors. It has been shown to inhibit the activity of survivin and Flt3 tyrosine kinase in mouse tumor models. CCT241736 also inhibits the growth of human colon cancer cells in vitro and has a good oral bioavailability. The drug was found to be selective for Flt3-ITD, which is responsible for the activation of the receptor tyrosine kinase Fms-like Tyrosine Kinase 3 (FLT3). This inhibition prevents tumor progression by blocking downstream signals from this receptor, leading to cell death.

Fórmula: C₂₂H₂₃Cl₂N₇

Pureza: Min. 95%

Peso molecular: 456.37 g/mol

Ref: 3D-CGC70993